Wound Care Biologics Market Size & Share 2026-2035

Wound Care Biologics Market Size

The global wound care biologics market was valued at USD 2 billion in 2025 and is projected to grow from USD 2.1 billion in 2026 to USD 3.5 billion by 2035, expanding at a CAGR of 5.9%, according to the latest report published by Global Market Insights Inc.

The developing and underdeveloped regions have been observing an increasing number of burn wounds. Thus, the demand of wound care biologics is further increasing. The lack of severe medical attention, inadequate facilities, and increased chances of infection prolong the healing of the wound with many complications especially in the underdeveloped regions. For instance, according to the World Health Organization (WHO), roughly 180,000 fatalities are caused due to burns each year with the majority of these coming from lower and medium-income countries.

Furthermore, every year, more than 6 million people face the problem of suffering from burns that are moderate to severe which results in increased hospital admissions. The recognition of biologic solutions using advanced wound care, is positively transforming patient outcomes alongside the difficulties of burn infection control and tissue regeneration. The top 5 players in this market are Organogenesis, MiMedx Group, Smith & Nephew, Integra LifeSciences and Kerecis.

Moreover, the global surge in the elderly demographic is shifting its focus towards the demand for wound care biologics due to geriatric population suffering from chronic wounds such as pressure ulcers, diabetic foot ulcers, and venous leg ulcers. The United Nations (UN) estimates that the world population aged 65 years and above is expected to reach 1.6 billion by 2050, which is nearly double the 761 million from 2021. In addition, over 15% of the elderly population is estimated to be suffering from chronic wounds which increases the amount of time and money spent on the healthcare system. Wound care biologics aid in tissue repair for the increasing elderly population and reduce complications, thereby boosting the market growth.

Wound care biologics are advanced bioengineered products aimed at assisting in curing non-healing wounds, by stimulating the body’s natural healing mechanisms. Such advanced treatments are designed to trigger the body’s innate healing capabilities, minimizing the chances of function and mobility loss, including amputation.

Wound Care Biologics Market Trends

• Rise in demand of regenerative wound care biologics, such as growth factors, skin substitutes, and extracellular matrix-based products, by healthcare providers is accelerating the market development. These products facilitate healing chronic wounds such as diabetic foot ulcers and pressure ulcers.
•  Key players are expanding their biologics portfolio to provide more comprehensive and targeted healing products. For instance, Apligraf, a bi-layered skin substitute developed by Organogenesis, has a high healing rate in venous leg ulcers. Similarly, Smith & Nephew’s GrafixPL has also been improving healing in diabetic foot ulcers.
•  Furthermore, ready-to-use biologic dressings and grafts are more preferable than tissue-based autologous therapies because of their ease-of-use and lesser time needed for preparation.
•  Another advancing trend is the rise of home-based wound management, driven by telehealth adoption and portable biologic dressing solutions. The growth of the home healthcare market, which is expected to reach USD 555.6 billion by 2032, is further supporting this shift.
•  In addition to this, another focus area for manufacturers is sustainable packaging solutions by using biodegradable materials and minimizing plastic waste. Companies are investing in eco-friendly alternatives, such as bio-based polymers, for wound biologics packaging.
•  For instance, Molnlycke has implemented sustainable manufacturing processes for its wound care biologics, reducing carbon emissions by 20% and cutting plastic usage by 30% in packaging. Such innovative product launches are contributing to the progression of the market.

Wound Care Biologics Market Analysis

Based on product type, the wound care biologics market is segmented into skin substitutes and topical agents. The skin substitutes segment dominated the market with the largest revenue of USD 1.3 billion in 2025.

• Skin substitutes segment dominated the market as they provide structural support and promote tissue regeneration in chronic and acute wounds. These solutions can be derived from human, animal, or synthetic sources, and are designed to improve wound healing.
•  Increasing chronic wounds is a leading cause of this segment’s dominance. According to the International Diabetes Federation (IDF), it is estimated that 19 –34% of diabetic patients will develop a foot ulcer in their lifetime, with over 9.1 –26.1 million diabetic foot ulcer (DFU) cases annually worldwide.
•  Moreover, skin substitutes help in reducing wound closure time, as well as minimizing infection risks in various cases of diabetic foot ulcers, pressure ulcers and burn injuries, hence boosting segmental growth.

Based on wound type, the wound care biologics market is segmented into diabetic foot ulcers, venous leg ulcers, pressure ulcers, surgical wounds, burns and other wound types. The surgical wounds segment emerged as a dominant segment in the market, accounting for 26.8% of revenue share in 2025.

• The segment is dominant due to an increase in the need for healthcare professionals to minimize surgical site infections (SSIs), enhance tissue regeneration, and expedite healing post-surgery.
•  This demand is further fueled by the increasing elderly population and growing orthopedic, cardiovascular, and reconstructive procedures. According to the WHO, there are approximately 313 million surgical procedures carried out globally every year, many of which are accompanied by advanced wound care needs.
•  Thus, the increased surgery burden is responsible for the high market share of this segment in the market.

Based on end use, the wound care biologics market is segmented into hospitals, ambulatory surgical centers, and other end users. Hospitals segment accounted for the largest revenue share of 43.7% in 2025.

• The primary users of wound care biologics are the hospitals which are important in the management of acute and chronic wounds such as diabetic foot ulcers, pressure ulcers, burns, and post-surgical wounds.
•  The increased utilization of biologic wound care products by hospitals is because of the adoption of advanced skin substitutes, growth factor therapies, and collagen-based dressings, which all strive to enhance the healing outcomes and decrease infection rates.
• Further, the market growth for biologics is boosted by specialized outpatient and wound care settings that incorporate biologics into their treatment protocols for complex wounds.
•  Hospitals are expanding their regenerative therapy services by adding placental tissue allografts and autologous cell-based therapies due to an increase in diabetes and vascular diseases for higher wound closure rates, thereby boosting the adoption of wound care biologics and further driving the segmental growth.

North America Wound Care Biologics Market

• North America held the largest share of the global wound care biologics industry in 2025, supported by advanced healthcare infrastructure, high adoption of advanced wound‑management therapies, and strong clinical awareness of biologic‑based solutions for complex and chronic wounds. The region has been an early adopter of skin substitutes, growth factors, and bioengineered tissue products across acute and post‑acute care settings.
• The market is reinforced by well‑defined and mature regulatory frameworks, particularly under the U.S. FDA and Health Canada, which provide structured pathways for biologics approval.
• A high and growing burden of chronic wounds is a key driver of North America’s market leadership. Rising prevalence of diabetes, obesity, cardiovascular disease, and an aging population has led to increasing incidence of diabetic foot ulcers, venous leg ulcers, pressure ulcers, and surgical wounds. This epidemiological profile has intensified demand for advanced biologics that promote faster healing, reduce infection risk, and lower long‑term treatment costs.
• With ongoing innovation in bioengineered skin substitutes, extracellular matrix products, and regenerative therapies, alongside expanding outpatient wound management and value‑based care models, North America is expected to maintain its leading position over the forecast period.

The U.S. market size reached USD 691.6 million in 2025, growing from USD 660.4 million in 2024.

• The substantial and growing burden of chronic wounds in the U.S. creates a highly conducive environment for the adoption of wound care biologics. Chronic wounds significantly impair patient mobility, productivity, and overall, well‑being. According to the National Institutes of Health (NIH), as of 2022, chronic wounds affected the quality of life of approximately 2.5% of the total U.S. population, highlighting the scale of unmet clinical need and the importance of advanced therapeutic interventions.
• The rising prevalence of diabetes is a critical demand‑side driver for the U.S. wound care biologics market. As reported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), more than 38.4 million individuals in the U.S. were living with diabetes as of 2021. Given that up to 34% of patients with type 1 or type 2 diabetes are at risk of developing diabetic foot ulcers, the clinical burden of hard‑to‑heal wounds is expected to intensify, directly expanding the addressable market for biologic wound‑healing solutions.
• High incidence of diabetic foot ulcers, venous leg ulcers, pressure ulcers, and post‑surgical wounds has accelerated clinical reliance on biologic therapies such as skin substitutes, cellular and tissue‑based products, and extracellular matrix grafts. These biologics are increasingly favored in U.S. clinical practice due to their ability to promote tissue regeneration, reduce healing time, and lower overall complication rates compared to conventional wound care approaches.

Europe Wound Care Biologics Market

Europe market accounted for USD 520.1 million in 2025 and is anticipated to show lucrative growth over the forecast period.

• Europe held a strong and well‑established position in the global wound care biologics industry in 2025, supported by its mature healthcare systems, extensive hospital and outpatient networks, and growing clinical adoption of advanced wound‑healing therapies. High standards of care and early uptake of evidence‑based treatment modalities have enabled consistent utilization of biologics across the region.
• European healthcare systems place strong emphasis on early intervention, standardized care pathways, and long‑term management of chronic conditions, which supports the integration of wound care biologics into routine clinical practice. Structured approaches to managing diabetic foot ulcers, venous leg ulcers, pressure ulcers, and post‑surgical wounds have driven demand for skin substitutes, cellular‑ and tissue‑based products, and extracellular matrix biologics.
• The region’s aging population and rising prevalence of chronic diseases, including diabetes and cardiovascular disorders, continue to increase the incidence of hard‑to‑heal wounds. This demographic and epidemiological profile reinforces the need for advanced biologic therapies that promote tissue regeneration, accelerate healing, and reduce recurrence and complication risks.

The market in UK is expected to experience significant and promising growth from 2026 to 2035.

• The UK represents an important market for wound care biologics, supported by one of the world’s most structured public healthcare systems, the National Health Service (NHS). The NHS plays a central role in the diagnosis, treatment, and long‑term management of both acute and chronic wounds, enabling systematic adoption of advanced wound‑care solutions, including biologic therapies, across hospital and community care settings.
• The growing burden of chronic wounds in the UK is a key factor driving market expansion. According to NHS estimates, approximately 3.8 million individuals across the country suffer from wounds each year, with a significant proportion experiencing chronic, non‑healing wounds. This high clinical burden places sustained pressure on healthcare resources and reinforces the need for advanced biologic treatments that can accelerate healing and reduce recurrence.
• An aging population significantly amplifies demand for wound care biologics in the UK. Individuals aged 65 years and above are at higher risk of developing chronic wounds, including pressure ulcers, venous leg ulcers, and diabetic foot ulcers, due to comorbidities, reduced skin integrity, and impaired healing capacity. As the proportion of elderly residents continues to rise, the incidence of complex and hard‑to‑heal wounds is expected to increase.

Asia Pacific Wound Care Biologics Market

The Asia Pacific region is projected to show lucrative growth of about 6.8% during the forecast period.

• Asia Pacific is emerging as one of the fastest‑growing regions in the global wound care biologics industry, driven by its large population base, rising prevalence of chronic diseases, and increasing awareness and adoption of advanced wound‑care therapies across both developed and emerging economies in the region.
• The region comprises mature healthcare markets such as Japan, Australia, South Korea, and Singapore, where adoption of advanced wound care solutions, including biologic skin substitutes and regenerative therapies, is well established, alongside rapidly expanding markets such as China, India, and Southeast Asia, which are strengthening healthcare infrastructure and expanding access to advanced wound‑management products.
• The clinical burden of chronic wounds is significant across Asia Pacific, fueled by high and growing rates of diabetes, cardiovascular disease, obesity, and trauma‑related injuries. Diabetic foot ulcers, venous leg ulcers, pressure ulcers, and post‑surgical wounds represent major sources of morbidity, driving demand for biologics that can accelerate healing and improve clinical outcomes.
• With its large and aging population, rising chronic‑disease burden, expanding healthcare infrastructure, and growing acceptance of regenerative and biologic wound‑care solutions, Asia Pacific is expected to remain one of the fastest‑growing regions in the global wound care biologics market over the forecast period.

Japan market is anticipated to witness lucrative growth between 2026 and 2035.

• Japan represents a highly attractive and steadily expanding market for wound care biologics, largely due to its rapidly aging population and advanced healthcare system. The country is experiencing one of the most pronounced demographic shifts globally. According to Statista, as of November 2023, approximately 36.35 million individuals in Japan were aged 65 years and above, underscoring the scale of age‑related healthcare demand.
• This super‑aging demographic profile significantly elevates the incidence of chronic and hard‑to‑heal wounds, including pressure ulcers, venous leg ulcers, diabetic foot ulcers, and post‑surgical wounds. Elderly patients are more susceptible to impaired wound healing due to reduced skin integrity, limited mobility, and a high prevalence of comorbidities, creating sustained demand for advanced and regenerative wound‑care solutions.
• As disease complexity rises within Japan’s aging society, the need for robust and effective wound management systems is becoming increasingly urgent. Healthcare providers are actively integrating biologic wound therapies into chronic wound treatment strategies to improve quality of life, reduce caregiver burden, and curb long‑term healthcare costs.
• With its massive elderly population, growing chronic wound burden, and continued advancements in regenerative medicine, Japan is expected to witness sustained growth in the wound care biologics market, positioning the country as a key contributor to Asia Pacific market expansion over the forecast period.

Latin America Wound Care Biologics Market

Brazil is experiencing significant growth in the wound care biologics industry.

• Brazil represents one of the most important and rapidly expanding wound care biologics markets in Latin America, supported by its large population base, rising prevalence of chronic diseases, and increasing demand for advanced wound‑management solutions across both public and private healthcare systems.
• The growing burden of chronic wounds, particularly diabetic foot ulcers, venous leg ulcers, pressure ulcers, and post‑surgical wounds, is a key driver of market growth in Brazil. High rates of diabetes, obesity, cardiovascular disease, and trauma‑related injuries continue to strain conventional wound‑care approaches, creating sustained demand for biologic therapies that promote faster and more effective healing.
• As healthcare providers seek to reduce long‑term treatment costs, hospital stays, and complication rates, wound care biologics are increasingly viewed as a valuable therapeutic option that can improve healing outcomes and lower the overall burden on the healthcare system.
• With growing investment in healthcare infrastructure, increasing awareness of advanced wound‑healing therapies, and expanding access through private healthcare facilities, Brazil is expected to remain a key growth market for wound care biologics in Latin America over the forecast period.

Middle East and Africa Wound Care Biologics Market

The market in Saudi Arabia is expected to experience significant and promising growth from 2026 to 2035.

• Saudi Arabia is increasingly emerging as a strategic growth market for wound care biologics, driven by the Kingdom’s healthcare modernization agenda and expanding investment in advanced medical technologies under the Vision 2030 framework. A strong focus on improving clinical outcomes, reducing long‑term care costs, and elevating specialist care capabilities is accelerating adoption of biologic wound‑healing solutions.
• Saudi Arabia is also experiencing an aging population. For instance, the number of people aged 60 and above are expected to rise five times from 2 million (5.9% of the total population) in 2020, reaching 10.5 million by 2050.
•  Such high trends in the aging population are expected to increase the demand for wound care biologics in coming years.
• With sustained healthcare investment, expanding access to advanced wound‑care services, and alignment between Vision 2030 objectives and adoption of regenerative biologics, Saudi Arabia is well positioned to become one of the most influential wound care biologics markets in the Middle East, driving long‑term growth and regional leadership over the forecast period.

Wound Care Biologics Market Share

• The wound care biologics industry is highly competitive, characterized by the presence of well‑established global leaders alongside specialized regenerative‑medicine companies focused on advanced skin substitutes and biologic wound‑healing solutions. Market participants compete through continuous product innovation, expansion of biologic and regenerative platforms, robust clinical evidence generation, and strong relationships with healthcare providers, wound‑care clinics, and payer systems.
• Leading players such as Organogenesis, MiMedx Group, Smith & Nephew, Integra LifeSciences, and Kerecis collectively account for a significant share of the wound care biologics market. These companies benefit from broad and differentiated portfolios spanning biologic skin substitutes, placental and cellular allografts, extracellular matrix scaffolds, and xenograft‑based regenerative materials, addressing both chronic and acute wound indications.
• Overall, competitive dynamics in the wound care biologics industry are shaped by innovation in regenerative medicine, increasing clinical reliance on biologic skin substitutes for hard‑to‑heal wounds, expanding reimbursement support, and rising demand driven by aging populations and chronic disease prevalence. Strategic acquisitions, product line extensions, and investment in real‑world evidence generation continue to define competition and differentiation among leading players.

Wound Care Biologics Market Companies

Some of the eminent market participants operating in the wound care biologics industry include:

• 3M
• Amnio Technology
• Avita Medical
• Celularity Inc.
• Convatec
• Derma Sciences
• Integra Life Sciences
• Kerecis
• MiMedx Group
• Organogenesis
• Osiris Therapeutics
• Smith & Nephew
• Tides Medical
• Vericel Corporation

• Smith & Nephew

Smith & Nephew is a global leader in the wound care biologics market, distinguished by its strong integration of placental‑derived biologics and advanced wound‑management solutions. Through its Osiris Therapeutics portfolio the company delivers clinically validated biologic skin substitutes for complex and hard‑to‑heal wounds.

• Integra LifeSciences

Integra LifeSciences is a well‑established innovator in regenerative medicine, with deep expertise in extracellular matrix‑based and collagen‑derived wound care biologics. The company’s strong emphasis on biomaterial science, combined with broad adoption across hospitals and specialty surgical centers, positions Integra as a key enabler of advanced biologic wound‑healing strategies.

• Kerecis

Kerecis is recognized for its differentiated leadership in fish‑skin xenograft technology, offering biologic wound‑care products that closely mimic the natural human extracellular matrix. Strong clinical outcomes, expanding global adoption, and growing use in both chronic wounds and burns position Kerecis as one of the most innovative players in the wound care biologics market.

Wound Care Biologics Industry News:

• In March 2022, Convatec Group Plc acquired Triad Life Sciences Inc., a U.S. based medical device company which was a manufacturer of biologically derived products for surgical wounds, chronic wounds, and burns. This acquisition marked Convatec’s entry into the wound care biologics industry, enhancing its portfolio to address unmet clinical needs.
• In September 2022, MiMedx Group, Inc. introduced AMNIOEFFECT, a tri-layer PURION processed human tissue allograft designed for surgical wound management. This innovation enhanced the company’s surgical recovery portfolio and strengthened its position in this market owing to the introduction of this new product.

The wound care biologics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Skin substitutes
  • Biological
    • Allograft
    • Xenograft
    • Other biological skin substitutes
  • Synthetic
• Topical agents

Market, By Wound Type

• Diabetic foot ulcers
• Venous leg ulcers
• Pressure ulcers
• Surgical wounds
• Burns
• Other wound types 

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE